Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRGX 
CARGO Therapeutics, Inc. Common Stock (CRGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/20/2025: CRGX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.64% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 216.19M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 3.00 - 25.45 | Updated Date 08/29/2025 |
52 Weeks Range 3.00 - 25.45 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.62 |
Earnings Date
Report Date 2025-08-20 | When - | Estimate -1.3 | Actual -1.04 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.91% | Return on Equity (TTM) -65.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -35800530 | Price to Sales(TTM) - |
Enterprise Value -35800530 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -12.16 | Shares Outstanding 48364300 | Shares Floating 30040041 |
Shares Outstanding 48364300 | Shares Floating 30040041 | ||
Percent Insiders 0.63 | Percent Institutions 99.29 |
Upturn AI SWOT
CARGO Therapeutics, Inc. Common Stock
Company Overview
History and Background
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. Founded in 2020 and went public in November 2023, it aims to address unmet needs in patients with hematologic malignancies.
Core Business Areas
- Cell Therapy Development: CARGO focuses on developing CAR-T cell therapies targeting hematologic malignancies.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its CAR-T cell therapy candidates.
- Manufacturing: Developing and scaling up manufacturing processes for CAR-T cell therapies.
Leadership and Structure
CARGO Therapeutics is led by CEO Gina Chapman. The organizational structure consists of research and development, clinical operations, manufacturing, and administrative functions.
Top Products and Market Share
Key Offerings
- CRG-801: CRG-801 is CARGO Therapeutics' lead CAR-T cell therapy candidate targeting relapsed or refractory chronic lymphocytic leukemia (CLL) and B-cell lymphomas. Early clinical trial data suggests promising efficacy and safety. Competitors include companies developing similar CAR-T therapies such as Novartis (Kymriah) and Gilead (Yescarta).
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, with significant investment and innovation in CAR-T cell therapies and other cell-based treatments for cancer and other diseases.
Positioning
CARGO Therapeutics is positioning itself as a leader in next-generation CAR-T cell therapies with a focus on improving efficacy, safety, and accessibility.
Total Addressable Market (TAM)
The total addressable market for CAR-T cell therapies is expected to reach billions of dollars annually. CARGO Therapeutics is positioned to capture a share of this market with its innovative CAR-T cell therapy candidates.
Upturn SWOT Analysis
Strengths
- Promising early clinical data for lead CAR-T candidate
- Experienced management team
- Strong focus on next-generation CAR-T cell therapies
Weaknesses
- Early-stage company with limited revenue
- Dependence on successful clinical trial outcomes
- High development costs
Opportunities
- Expanding CAR-T cell therapy applications to other cancers
- Partnerships with larger pharmaceutical companies
- Regulatory approvals for CAR-T cell therapy candidates
Threats
- Competition from established CAR-T cell therapy companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
Competitive Landscape
CARGO Therapeutics faces intense competition from established CAR-T cell therapy companies like Gilead and Novartis. To succeed, CARGO must demonstrate superior efficacy and safety with its CAR-T cell therapy candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent founding.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst projections vary, but generally anticipate significant revenue growth in the coming years if CRG-801 is approved.
Recent Initiatives: Recent initiatives include progressing CRG-801 through clinical trials, expanding manufacturing capacity, and exploring potential partnerships.
Summary
CARGO Therapeutics is a clinical-stage biotech company with a promising CAR-T cell therapy candidate, CRG-801. While it faces competition from established players, its focus on next-generation therapies provides potential for growth. Successful clinical trial outcomes and regulatory approvals are critical for its future. Its financial stability is secured with 284.8 million in cash and marketable securities, offering a buffer against operational losses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Earnings Calls Transcripts
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CARGO Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2023-11-10 | Interim CEO, CFO, Secretary, COO & Director Mr. Anup Radhakrishnan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 167 | Website https://cargo-tx.com |
Full time employees 167 | Website https://cargo-tx.com | ||
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Carlos, California. As of August 18, 2025, CARGO Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.